Lecithin: Cholesterol acyl transfer rate and high density lipoproteins in plasma during dietary and clofibrate treatment of hypertriglyceridemic subjects

      This paper is only available as a PDF. To read, Please Download here.


      Effects of lipid-lowering treatment on the lecithin: cholesterol acyl transfer (LCAT) rate and the concentrations of lipids and high density lipoproteins (HDL) lipids in plasma were determined in hypertriglyceridemic subjects. Thirty-nine subjects were studied before and after two months on a weight reducing diet. Twenty subjects were studied also one month after the addition of clofibrate to the dietary regimen.
      After two months on the diet the mean body weight had decreased by 4.5%. There were reductions in the mean plasma concentrations of triglycerides (TG) by 18% and in total cholesterol (TC), unesterified cholesterol (UC) and phospholipids (PL) by 12%. The mean HDL-TC concentrations increased by 10%, while the mean HDL-PL concentration was unchanged. During two months of diet the mean molar LCAT rate decreased by 17% and the mean fractional LCAT rate was reduced by 6%.
      One month after the addition of clofibrate there were reductions in the mean plasma concentrations of TG by 43% and of TC, UC and PL by 15%. The mean HDL-TC concentration increased by 22%, while the mean HDL-PL concentration was enhanced by 9%. The mean molar LCAT rate decreased by 10%, based on reductions in the type IV subjects with high molar LCAT rates before the clofibrate treatment. The mean fractional LCAT rate was not changed in the type IV subjects but increased in the type IIb and type III subjects during clofibrate therapy.
      The changes in the molar LCAT rate correlated positively with the changes in the body mass after two months on the diet and with the changes in the concentrations of TG, UC and PL in plasma obtained with both kinds of treatment. The changes in the fractional LCAT rate were negatively correlated with the changes of low density lipoprotein-TC concentrations during both kinds of treatment.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Glomset J.A.
        Plasma lecithin: cholesterol acyltransferase.
        in: Nelson G.J. Blood Lipids and Lipoproteins. Wiley Interscience, New York, NY1972
        • Glomset J.A.
        • Norum K.R.
        The metabolic role of lecithin: cholesterol acyltransferase.
        Advanc. Lipid Res. 1973; 2: 1
        • Nestel P.J.
        Cholesterol turnover in man.
        Advanc. Lipid Res. 1970; 8: 1
        • Akanuma Y.
        • Kuzuya T.
        • Hayashi M.
        • Ide T.
        • Kuzuya N.
        Positive correlation of serum lecithin: cholesterol acyl transferase activity with relative bodyweight.
        Europ. J. Clin. Invest. 1973; 3: 136
        • Fabien H.D.
        • Davignon J.a
        • Marcel Y.L.
        Plasma cholesterol esterification in normal and hyperlipoproteinemic subjects.
        Canad. J. Biochem. 1973; 51: 35
        • Blomhoff J.P.
        In vitro determination of lecithin: cholesterol acyltransferase activity in plasma.
        Scand. J. Clin. Lab. Invest. 1974; 33: 35
        • Kudchodkar B.J.
        • Sodhi H.S.
        Turnover of plasma cholesteryl ester and its relationship to other parameters of lipid metabolism in man.
        Europ. J. Clin. Invest. 1976; 6: 285
        • Wallentin L.
        • Vikrot O.
        Lecithin: cholesterol acyl transfer in plasma of normal persons in relation to lipid and lipoprotein concentration.
        Scand. J. Clin. Lab. Invest. 1975; 35: 669
        • Miller N.E.
        • Nestel P.J.
        • Clifton-Bligh P.
        Relationships between plasma lipoprotein cholesterol concentration and the pool size and metabolism of cholesterol in man.
        Atherosclerosis. 1976; 23: 535
        • Rose H.G.
        • Juliano J.
        Regulation of plasma lecithin: cholesterol acyltransferase in man, Part 1 (Increased activity in primary hypertriglyceridemia).
        J. Lab. Clin. Med. 1976; 88: 29
        • Rose H.G.
        • Juliano J.
        Regulation of plasma lecithin: cholesterol acyl transferase, Part 2 (Activation during alimentary lipemia).
        J. Lab. Clin. Med. 1977; 89: 524
        • Wallentin L.
        Lecithin: cholesterol acyl transfer rate in plasma and its relation to lipid and lipoprotein concentrations in primary hyperlipidemia.
        Atherosclerosis. 1977; 26: 233
        • Wallentin L.
        Influence of intravenous and oral administration of phospholipids on lecithin: cholesterol acyl transfer rate in plasma.
        Artery. 1977; 3: 40
        • Gjone E.
        • Nordöy A.
        • Blomhoff J.P.
        • Wiencke I.
        The effects of unsaturated and saturated dietary fats on plasma cholesterol phospholipids and lecithin: cholesterol acyltransferase activity.
        Acta Med. Scand. 1972; 191: 481
        • Miller J.P.
        • Chait A.
        • Lewis B.
        The relationship between dietary fat composition and plasma cholesterol esterification in man.
        Clin. Sci. Mol. Med. 1975; 49: 617
        • Wallentin L.
        • Vikrot O.
        Influence of fat ingestion on lecithin: cholesterol acyl transfer rate in plasma of normal persons.
        Scand. J. Clin. Lab. Invest. 1976; 36: 473
        • Fredrickson D.S.
        • Levy R.I.
        Familial hyperlipoproteinemia.
        in: Stanbury J.B. Wyngarden J.B. Fredrickson D.S. The Metabolic Basis of Inherited Disease. 3rd edition. McGraw-Hill, New York, NY1972
      1. (DREW Publication No. (NIH)75-628)6th edition. Manual of Laboratory Operations. Vol. 1. National Heart and Lung Institute, National Institute of Health, Bethesda, MD1974 (Lipid and Lipoprotein Analysis)
        • Olsson A.G.
        • Carlsson L.A.
        Studies in asymptomatic primary hyperlipidaemia, Part 1 (Types of hyperlipoproteinaemias and serum lipoprotein concentrations, compositions and interrelations).
        Acta. Med. Scand. 1975;
        • Wallentin L.
        • Vikrot O.
        Evaluation of an in vitro assay of lecithin: cholesterol acyl transfer rate in plasma.
        Scand. J. Clin. Lab. Invest. 1975; 35: 661
        • Stokke K.T.
        • Norum K.R.
        Determination of lecithin: cholesterol acyl transfer in human blood plasma.
        Scand. J. Clin. Lab. Invest. 1971; 27: 21
        • Vikrot O.
        Quantitative determination of plasma phospholipids in pregnant and nonpregnant women with special reference to lysolecithin.
        Acta Med. Scand. 1964; 175: 443
        • Snedecor G.W.
        • Cochran W.G.
        Statistical Methods.
        6th edition. Iowa State University Press, Ames, IA1973
        • D'Alessandro A.
        • Zucconi A.
        • Bellini F.
        • Boncinelli L.
        • Chiostri R.
        Lecithin: cholesterol acyltransferase activity in hypercholesterolemic subjects and in hypercholesterolemic subjects treated with clofibrate.
        Lipids. 1975; 10: 804
        • Marcel U.L.
        • Vezina C.
        Lecithin: cholesterol acyl transferase of human plasma.
        Biochim. Biophys. Acta. 1973; 306: 497
        • Clifton-Bligh P.
        • Miller N.E.
        • Nestel P.J.
        Increased plasma cholesterol esterifying activity during colestipol resin therapy in man.
        Metabolism. 1974; 23: 437
        • Barter P.J.
        Production of plasma esterified cholesterol in lean normotriglyceridemic humans.
        J. Lipid Res. 1974; 14: 234
        • Miettinen T.
        Cholesterol production in obesity.
        Circulation. 1971; 44: 842
        • Nestel P.J.
        • Schreibman P.H.
        • Ahrens Jr., E.H.
        Cholesterol metabolism in human obesity.
        J. Clin. Invest. 1973; 52: 2389
        • Einarsson K.
        • Hellström K.
        • Kallner M.
        Bile acid kinetics in relation to sex, serum lipids, body weight and gall bladder disease in patients with various types of hyperlipoproteinemia.
        J. Clin. Invest. 1974; 54: 1301
        • Bennion L.J.
        • Grundy S.M.
        Effects of obesity and caloric intake on biliary lipid metabolism in man.
        J. Clin. Invest. 1975; 56: 996
        • Smith F.R.
        • Dell R.B.
        • Noble R.P.
        • Goodman D.S.
        Parameters of the three pool model of the turnover of plasma cholesterol in normal and hyperlipidemic humans.
        J. Clin. Invest. 1976; 57: 137
        • Sigurdsson G.
        • Nicoll A.
        • Lewis B.
        Metabolism of very low density lipoproteins in hyperlipidaemia — Studies of apoprotein-B kinetics in man.
        Europ. J. Clin. Invest. 1976; 6: 167
        • White L.W.
        Mechanism of clofibrate inhibition of hepatic cholesterol biosynthesis.
        in: Jones R.J. Atherosclerosis (Proceedings of the Second International Symposium). Springer-Verlag, New York, NY1970
        • Bierman E.L.
        • Brunzell J.P.
        • Bagdade J.P.
        • Lerner R.L.
        • Hazzard W.R.
        • Porte Jr., D.
        On the mechanism of action of Atromid-S on triglyceride transport in man.
        Trans. Ass. Amer. Physcn. Philad. 1970; 83: 211
        • Horlick L.
        • Kudchodkar B.J.
        • Sodhi H.S.
        Mode of action of chlorophenoxyisobutyrate (CPIB) on cholesterol metabolism in man.
        Circulation. 1971; 43: 299
        • Barter P.J.
        • Nestel P.J.
        • Carroll K.F.
        Precursors of plasma triglyceride fatty acid in humans — Effects of glucose consumption, clofibrate administration and fatty liver.
        Metab. (Clin. Exp.). 1972; 21: 117
        • Grundy S.M.
        • Ahrens Jr., E.H.
        • Salen G.
        • Schreibman P.H.
        • Nestel P.J.
        Mechanism of action of clofibrate on cholesterol metabolism in patients with hyperlipidemia.
        J. Lipid Res. 1972; 13: 531
        • Nikkilä E.A.
        • Kekki M.
        Plasma endogenous triglyceride transport in hypertriglyceridemia and effect of hypolipidemic drug (SU-13437).
        Europ. J. Clin. Invest. 1972; 2: 231
        • Einarsson K.
        • Hellström K.
        • Kallner M.
        The effect of clofibrate on the elimination of cholesterol as bile acids in patients with hyperlipoproteinemia type II and IV.
        Europ. J. Clin. Invest. 1973; 3: 345
        • Boberg J.
        • Carlson L.A.
        • Fröberg S.O.
        • Orö L.
        Effect of a hypolipidemic drug (Ch 13437) on plasma and tissue lipids and on the intravenous fat tolerance in man.
        Atherosclerosis. 1970; 11: 353
        • Wilson D.E.
        • Lees R.S.
        Metabolic realtionships among plasma lipoproteins - Reciprocal changes in very low and low density lipoproteins in man.
        J. Clin. Invest. 1972; 51: 1051
        • Wolfe B.M.
        • Kane J.P.
        • Havel R.J.
        • Brewster H.P.
        Mechanism of the hypolipidemic effect of clofibrate in postabsorptive man.
        J. Clin. Invest. 1973; 52: 2146
        • Greten H.
        • Laible V.
        • Zipperle G.
        • Augustin J.
        Comparison of assay methods for selective measurements of plasma lipase.
        Atherosclerosis. 1977; 26: 563
        • Sodhi H.S.
        • Kudchodkar B.J.
        • Horlick L.
        Effect of chlorophenoxyisobutyrate on the metabolism of endogenous glycerides in man.
        Metab. (Clin. Exp.). 1971; 20: 309
        • Weis A.S.
        • Tepperman H.M.
        • Tepperman J.
        Effects of chlorophenoxyisobutyrate (CPIB) on serum insulin levels, insulin sensitivity and adipose tissue cyclic AMP concentration.
        Endocrinology. 1973; 93: 504
        • Kissebah A.H.
        • Adams P.W.
        • Harrigan P.
        • Wynn V.
        The mechanism of action of clofibrate and tetranicotinyl fructose (Bradilan) on the kinetics of plasma free fatty acid and triglyceride transport in type IV hypertriglyceridemia.
        Europ. J. Clin. Invest. 1974; 4: 163
        • D. Costa M.A.
        • Angel A.
        Inhibition of hormone-stimulated lipolysis by clofibrate.
        J. Clin. Invest. 1975; 55: 138
        • Nikkilä E.A.
        • Huttunen J.K.
        • Ehnholm C.
        Effect of clofibrate on postheparin plasma triglyceride lipase activities in patients with hypertriglyceridemia.
        Metabolism. 1977; 26: 179
        • Nichols A.V.
        • Smith L.
        Effects of very low density lipoproteins on lipid transfer in incubated serum.
        J. Lipid. Res. 1965; 6: 206